References

  • Miller R. G., Rosenberg J. A., Gelinas D. F., , and the ALS Practice Parameters Task Force, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence‐based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1999; 52: 1311–23
  • Borasio G. D., Voltz R., Miller R. G. Palliative Care in Amyotrophic Lateral Sclerosis. Palliative Care. Neurol Clin, A Carver, K Foley, 2001; 19: 829–47
  • Ganzini L., Johnston W. S., Silveira M. J. The final month of life in patients with ALS. Neurology 2002; 59: 428–31
  • Amyotrophic Lateral Sclerosis. Completing a consensus document. Promoting Excellence in End‐of‐Life Care. A National Program of The Robert Wood Johnson Foundation, Project Report 29 April 2002.
  • Oliver D., Borasio G. D., Walsh D (editors). Palliative Care in Amyotrophic Lateral Sclerosis (Motor Neurone Disease). Oxford University Press, Oxford 2000
  • Mitsumoto H., Del Bene M. L. Improving the quality of life for people with ALS: the challenge ahead. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 329–36
  • World Health Organization. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990; 804: 1–75
  • Borasio G. D., Shaw P. J., Hardiman O., Ludolph A. C., Sales Luis M. L., Silani V. European ALS Study Group. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 159–64
  • Chio A., Silani V. Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers. J Neurol Sci 2001; 191: 145–50
  • Albert Murphy P. L., Del Bene M. L., Rowland L. P. Prospective study of palliative care in ALS: choice, timing, outcomes. J Neurol Sci 1999; 169: 108–13
  • Mitsumoto H., Chad D. A., Pioro E. P (editors). Psychological Management. Amyotrophic Lateral Sclerosis. Oxford Press, New York, NY 1998; 437–47
  • Neudert C., Wasner M., Borasio G. D. Patients' assessment of quality of life instruments: a randomized study of SIP, SF‐36 and SEIQoL‐DW in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 103–9
  • Rabkin J. G., Wagner G. J., Del Bene M. Resilience and distress among amyotrophic lateral sclerosis patients and caregivers. Psychosom Med 2000; 62: 271–9
  • Carver A. C., Vickrey B. G., Bernat J. L., Keran C., Ringel S. P., Foley K. M. End‐of‐life care: a survey of US neurologists' attitudes, behavior, and knowledge. Neurology 1999; 53: 284–93
  • Ganzini L., Lee M. A., Heintz R. T., Bloom J. D., Fenn D. S. The effect of depression treatment on elderly patients' preferences for life‐sustaining medical therapy. Am J Psychiatry 1994; 151: 1631–6
  • McDonald E. R., Wiedenfeld S. A., Hillel A., Carpenter C. L., Walter R. A. Survival in amyotrophic lateral sclerosis: the role of psychosocial factors. Arch Neurol 1994; 51: 17–23
  • McDonald E. R. Psychological, social, and spiritual factors. Amyotrophic Lateral Sclerosis. A Guide for Patients and Families, H Mitsumoto, T. L Munsat. Demos, New York, NY 2001; 283–97
  • Murphy M. M. Mourning. Amyotrophic Lateral Sclerosis, H Mitsumoto, T. L Munsat. Demos, New York 2001; 399–410
  • Murphy P. M., Albert S. M., Weber C. M., et al. Impact of spirituality and religiousness on outcomes in patients with amyotrophic lateral sclerosis. Neurology 2000; 55: 1581–4
  • Dal Bello‐Haas V., Andrews‐Hinders D., Bocian J., Mascha E., Wheeler T., Mitsumoto H. Spiritual well‐being of the individual with ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 337–41
  • Bromberg M. B., Forshew D. A. Comparison of instruments addressing quality of life in patients with ALS and their caregivers. Neurology 2002; 58: 320–2
  • Simmons Z., Bremer B. A., Robbins R. A., Walsh S. M., Fischer S. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000; 55: 388–92
  • Simmons P. Learning to fall: the blessings of an imperfect life. The Bantam Dell Publishing Group, New York, NY 2001
  • Robbins R. A., Simmons Z., Bremer B. A., Walsh S. M., Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology 2001; 56: 442–4
  • Clarke S., Hickey A., O'Boyle C., Hardiman O. Assessing individual quality of life in amyotrophic lateral sclerosis. Qual Life Res 2001; 10: 149–58
  • Cohen S. R., Mount B. M., Bruera E., Provost M., Rowe J., Tong K. Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi‐centre Canadian study demonstrating the importance of the existential domain. Palliat Med 1997; 11: 3–20
  • Mandler R. N., Anderson F. A Jr., Miller R. G., Clawson L., Cudkowicz M., Del Bene M., and the ALS CARE. Study Group. The ALS Patient Care Database: insights into end‐of‐life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 203–8
  • Ross M. A., Bradley W. G., Heiman‐Patterson T., Lyon M., Singleton C., Lessard D. The ALS caregivers: insight from the ALS Patient Care Database. Proceedings of the 10th International Symposium on ALS/MND, Vancouver, CA, November 8–10, 1999
  • Gelinas D. F., O'Connor P., Miller R. G. Quality of life for ventilator‐dependent ALS patients and their caregivers. J Neurol Sci 1998; 160((Suppl 1))S134–6
  • Goldstein L. H., Adamson M., Jeffrey L., et al. The psychological impact of MND on patients and carers. J Neurol Sci 1998; 160((Suppl 1))S114–21
  • Krivickas L. S., Shockley L., Mitsumoto H. Home care of patients with amyotrophic lateral sclerosis (ALS). J Neurol Sci 1997; 152((Suppl 1))S82–9
  • Benditt J. O., Smith T. S., Tonelli M. R. Empowering the individual with ALS at the end of life: disease‐specific advance care planning. Muscle Nerve 2001; 24: 1706–9
  • Ganzini L., Block S. Physician‐assisted death: a last resort?. N Engl J Med 2002; 346: 1663–5
  • Veldink J. H., Wokke J. H., van der Wal G., Vianney de Jong J. M., van den Berg L. H. Euthanasia and physician‐assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 2002; 346: 1638–44
  • Bradley W. G., Anderson F., Bromberg M., , and the ALS CARE Study Group, et al. Current management of ALS. Comparison of the ALS CARE Database and the AAN Practice Parameter., Neurology. 57. 500–4
  • Bernat J. L. Ethical and legal issues in palliative care. Neurol Clin 2001; 19: 969–87
  • Bernat J. L., Cranford R. E., Kittredge F. I., Rosenberg R. N. Competent patients with advanced states of permanent paralysis have the right to forego life‐sustaining therapy. Neurology 1993; 43: 224–5
  • Goldblatt D. Decisions about life support in amyotrophic lateral sclerosis. Semin Neurol 1984; 4: 104–10
  • Silverstein M. D., Stocking C. B., Antel J. P. Amyotrophic lateral sclerosis and life‐sustaining therapy: patients' desires for information, participation in decision making, and life‐sustaining therapy. Mayo Clin Proc 1991; 66: 906–13
  • Oliver D. The quality of care and symptom control: the effects on the terminal phase of ALS/MND. J Neurol Sci 1996; 139((Suppl 1))S134–6
  • The Medicare News Brief, Sept 1998; Issue MNB‐98‐7
  • Byock I. R., Forman W. B., Appleton M. Academy of Hospice Physicians' position statement on access to hospice and palliative care. J Pain Sympt Manage 1996; 11: 69–70
  • Lechtzin N., Wiener C. M., Clawson L., Chaudhry V., Diette G. B. Hospitalization in amyotrophic lateral sclerosis: causes, costs, and outcomes. Neurology 2001; 56: 753–7
  • Family Caregiving in the US. Findings from a National Survey. Final Report. National Alliance for Caregiving and the American Association of Retired Persons. June 1997; 4–40
  • Ackerman S. J., Sullivan E. M., Beusterien K. M., Natter H. M., Gelinas D. F., Patrick D. L. Cost effectiveness of recombinant human insulin‐like growth factor I therapy in patients with ALS. Pharmacoeconomics 1999; 15: 179–95
  • Ginsberg G. M., Lev B. Cost‐benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis. Pharmacoeconomics 1997; 12: 578–84
  • Messori A., Trippoli S., Becagli P., Zaccara G. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta‐Analysis and the Osservatorio SIFO sui Farmaci. Pharmacoeconomics 1999; 16: 153–63
  • Woolley J. M., Ringel S. P. The economics of amyotrophic lateral sclerosis. Neurology 1998; 50((Suppl A))A302
  • Emanuel E. J., Fairclough D. L., Slutsman J., Emanuel L. L. Understanding economic and other burdens of terminal illness: the experience of patients and their caregivers. Ann Intern Med 2000; 132: 451–9
  • Anderson F. A Jr., Miller R. G. ALS CARE Database: a resource for measuring and improving ALS outcomes. Neurology 1996; 47((Suppl 2))S113–5, discussion S115–6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.